	Application No.	Applicant(s)
Notice of Allowahility	10/790,260	DESMAZEAU ET AL.
Notice of Allowability	Examiner	Art Unit
·	David Lukton	1654
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>5/23/05</u> .		
2. The allowed claim(s) is/are 18-30 and 32-34.		
3. The drawings filed on are accepted by the Examiner.		
4. ☑ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☒ None of the: 1. ☒ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☐ hereto or 2) ☐ to Paper No./Mail Date (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying Indicts such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
 Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date	6. ⊠ Interview Summary Paper No./Mail Dat 08), 7. ⊠ Examiner's Amendn	te <u>20050701</u> .

Applicants' election of Group I with traverse is acknowledged, as is the elected specie. Applicant's traversal, however, is rendered moot, since claims 18-30, 32-34 are allowable, and since applicants have agreed to cancel claim 31.

4

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. §1.312. To ensure consideration of such an amendment, it <u>MUST</u> be submitted no later than the payment of the Issue Fee.

Cancel claim 31.

Authorization for this Examiner's Amendment was given in a telephone conversation with Balaram Gupta on 7/6/05.

In addition to the foregoing, there is an amendment to be made to the continuity status on page 1 of the specification. The amendment filed 3/2/04 directed insertion of the following on page 1, line 4 of the specification:

"This is a continuation of Application No. 09/643,197, filed August 22, 2000, which is a continuation of PCT/FR99/00409, filed February 24, 1999, both of which are incorporated herein by reference."

Delete the foregoing passage in its entirety, and substitute therefor the following:

- This is a continuation of application No. 09/643,197, filed August 22, 2000, now abandoned, which is a continuation of PCT/FR99/00409, filed February 24, 1999, both of which are incorporated herein by reference." Application PCT/FR99/00409 claims priority to French application 98/02316, filed 2/26/98. - -

The following is an examiner's statement of reasons for allowance:

The claimed compounds are novel over the art of record. In addition, applicants have shown that the compounds can be used to inhibit growth of bacteria.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

✦

Serial No. 10/790, 260 Art Unit 1653

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Lukton whose telephone number is 571-272-0952. The examiner can normally be reached Monday-Friday from 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell, can be reached at (571)272-0974. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

DAVID LUKTON PATENT EXAMINER GROUP 1890